TenQ · Stock reportUpdated 2026-10-22

AbbVie (ABBV)

$504.0B market cap · TenQ Score 24/36

Makes Humira, Skyrizi and Rinvoq for immune diseases, plus Botox and cancer drugs.

$285.19close as of 2026-10-22
+28.4% over 1Y · 12.8 points ahead of the S&P 500
$187.25$214.59$241.94$269.28$296.62Oct '25Jan '26Mar '26Jun '26Aug '26Oct '26

“How much more could acquired research and milestone expenses reduce AbbVie’s 2026 earnings guidance?”

Editorial note · updated 2026-10-06
The TenQ Radar

AbbVie in 36 checks

AbbVie on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.

VALUEGROWTHQUALITYFINANCIAL HEALTHSHAREHOLDERRETURNSTREND

A mixed picture, with strengths and real weaknesses: 24 of 36 checks passed.

The AbbVie story

What drives AbbVie, what its price assumes and what could change the story, written from its own filings.

  • Growth has accelerated. Revenue rose 10.4% over the last twelve months through June 2026, compared with annual growth of 1.8% over the last three years.
  • Immunology gets another investment. AbbVie completed its approximately $10.9 billion Apogee acquisition on September 3, 2026, adding clinical programs for inflammatory diseases.
  • Guidance remains conditional. AbbVie’s 2026 adjusted diluted EPS guidance of $13.76 to $13.96 excludes acquired research and milestone expenses incurred beyond the quarter to September 2026.

Read the AbbVie story

Advertisement
Latest earnings

AbbVie's latest earnings

Q3 '26 · quarter to 30 September 2026 · reported 5 October 2026 · Earnings release ↗

What the release says

The earnings summary is free with an account.

Sign up free to read it

AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q

Earnings alerts

An email when AbbVie reports, with its results and highlights. Free with a watchlist account.

I

Value

●●●●●●1/6

Expensive against its own history and its sector: the price asks a lot of the business.

80.1xown 10-year median 19.3x
7.8xown 10-year median 3.3x
3.6%cash earned per $ of price
31.7xwhole-business multiple
Valuation history

Is ABBV's P/E, P/S or P/B high or low against its own past?

→At 80.1x earnings, the market is paying +316% more than ABBV's own 10-year median of 19.3x. Expectations are elevated, so more has to go right to justify the price.

What this measures

What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.

What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.

If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.

Earnings yield

Does ABBV's earnings yield beat a 10-year Treasury?

→At today's price, ABBV earns 1.2% of its share price in profit a year, less than the 5.1% a 10-year Treasury pays.

What this measures

Earnings yield is profit per share divided by the share price: 1 ÷ P/E. It is the profit you buy with each dollar of share price. The 10-year US Treasury yield is what the government pays, with no risk to the payment, for lending to it for ten years.

What good looks like. An earnings yield above the Treasury yield: each dollar in the shares buys more profit than the same dollar earns in a government bond.

If it rises or falls. It falls when the share price rises faster than profit, and the bar rises when interest rates do: a higher Treasury yield makes the same shares harder to justify. A company whose profit is growing fast can sit below the line for years, which is what the price is betting on.

Free cash flow yield

What is ABBV's free cash flow yield at today's price?

→Every dollar of market value currently buys 3.6% of annual free cash flow, less than its 10-year median of 11.4% - you are paying up for the same cash.

What this measures

Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.

What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.

If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.

Enterprise value

What is ABBV's EV/EBITDA: the price of the whole business, debt included?

→Buying ABBV outright - equity plus debt, less the cash - costs 31.7x its EBITDA, above the 14.0x a broad market median sits at. Its own history runs at 16.3x, so the whole business is dearer than usual.

What this measures

Enterprise value over EBITDA. Enterprise value is the market value of the equity plus debt, less cash and short-term investments - what it would cost to buy the whole company outright. EBITDA is operating profit before depreciation and amortisation.

What good looks like. A multiple below what similar businesses change hands at, and one that has not run far above the company's own past.

If it rises or falls. It rises when the price rises or profit falls, and debt moves it too: two companies on the same price-to-earnings can sit far apart here if one is carrying borrowings the other is not.

Reverse discounted cash flow

What growth is priced into ABBV's shares?

Growth priced infree cash flow after stock pay, a year, next ten years12.9%
Growth deliveredfree cash flow after stock pay, a year, last 10 years13.9%
What the check allowsits record, slowing halfway to the economy's 4%9.0%
Value ABBV on your own assumptionsFree DCF calculator, pre-filled from its filings

→At $285.19 a share, ABBV's price assumes its free cash flow after stock pay grows 12.9% a year for the next ten years. Over the last 10 years it grew 13.9% a year. Allowing for that pace to slow, the check asks for no more than 9.0%: the price asks for more.

What this measures

A reverse discounted cash flow. It takes what the market pays for the shares today (market value less the cash the company holds) and works out how fast free cash flow would have to grow each year, for ten years, to be worth exactly that. Free cash flow here is after the stock the company pays its staff, which dilutes every other shareholder, and after interest, so debt is already paid for in it. Future cash is discounted at the 10-year Treasury yield plus 5 points, and grows 2.5% a year after year ten.

What good looks like. A priced-in rate below what its record suggests: the free cash flow growth it delivered over the longest span its filings allow, slowed halfway toward the economy's growth, because very few companies keep a past pace for another decade.

If it rises or falls. It rises when the share price rises or free cash flow falls, and when interest rates rise: a higher Treasury yield means the same price needs more growth to justify it.

What does “Value” actually mean?

Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.

How we scored it · 1 of 6 checks passed
✕Cheaper than its own history (earnings)80.13 vs 19.25
✕Earnings yield beats the 10-year Treasury (5.1%)1.2% vs 5.1%
✕Better cash yield than its own history3.6% vs 11.4%
✓Free cash flow yield above 3%3.6% vs 3.0%
✕Cheap on enterprise value (under 14x EBITDA)31.72 vs 14.00 (fixed yardstick)
✕Priced for less growth than its record suggests12.9% a year priced in vs 9.0%: 13.9% free cash flow growth over the last 10 years, slowing halfway to 4.0%
II

Growth

●●●●●●3/6

Growing, with caveats: revenue +10.4% over the last year.

+10.4%vs the year before
+1.8%compound annual
+67.7%net income growth
-29.1%compound annual
Revenue history

Is ABBV's revenue growing?

→Revenue reached $61.2B in 2025, compounding +2% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $64.4B, ahead of the last full year.

What this measures

The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.

What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.

If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.

Revenue by regionInsight

Where does AbbVie's revenue come from?

This insight is free with an account.

Sign up free to see it

→AbbVie makes 76% of its revenue from United States ($46.6B), and that share has risen from 66% in FY2018: the mix is shifting towards United States.

Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30

Profit history

Is ABBV's net profit growing?

→Net income was $4.2B in 2025, compounding -29% a year over three years. Earnings per share moved +68% over the last twelve months. Trailing twelve-month profit stands at $6.3B.

What this measures

What is left after every cost, including tax and interest. The bottom line of the income statement.

What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.

If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.

Growth rate

How fast are ABBV's revenue and earnings growing?

→Revenue grew 10% over the twelve months to 2026-06-30, against an average of +6% a year over 2021-2025. Earnings grew faster (68%), so each new dollar of sales is arriving more profitably.

What this measures

How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.

What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.

If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.

Per-share growth

Are ABBV's revenue and free cash flow per share growing?

→Revenue per share reached $34.50 in 2025, compounding +2% a year - in line with ABBV's own +2%, so the share count is not distorting your slice. The trailing twelve months are running at $36.31 a share. Free cash flow per share stands at $10.05.

What this measures

Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.

What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.

If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.

What does “Growth” actually mean?

Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).

How we scored it · 3 of 6 checks passed
✕Outgrew its sector over the last twelve months10.4% vs 20.4% (sector 70th pct, n=256)
✕Sustained growth beats its sector (3 years)1.8% vs 18.5% (sector 70th pct, n=251)
✓Profits grew over the last twelve months67.7% vs 0.0%
✕Profit growth beats its sector (3 years)-29.1% vs 15.4% (sector 70th pct, n=80)
✓Growth is speeding up, not slowinglast twelve months 10.4% vs three-year pace 1.8%
✓Grew per share, not just in total5.6% vs 0.0%
III

Quality

●●●●●●5/6

Rare profitability: margins and returns on capital are well above its peers.

71.5%kept after direct costs
26.2%kept after running costs
-profit on shareholders' money
18.0%against a 10% cost of capital
309%operating cash ÷ net income
Margins

What profit margin does ABBV keep on each sale?

→Operating margin compressed 7 points to 25% since 2022. After everything, 7 cents of each sales dollar reaches net profit.

What this measures

What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.

What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.

If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.

Earnings quality

Does ABBV's operating cash flow keep up with its profit?

→Operating cash flow runs at 309% of reported profit, so the earnings are more than backed by cash - depreciation and other non-cash charges are understating what the business actually collects.

What this measures

Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.

What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.

If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.

Returns on capital

What return on equity and on capital does ABBV earn?

→ROE of 63% sits well above ROCE of 18%. A meaningful share of the shareholder return is manufactured with leverage rather than operations.

What this measures

Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).

What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.

If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.

Income waterfall

Where does ABBV's revenue go, from sales to net profit?

→Of $64.4B over the twelve months to 2026-06-30 sales, $46.0B survives production costs, $16.9B survives running the company, and $6.3B - 10¢ of every dollar - reaches the bottom line.

What this measures

One year of revenue, with each major cost taken out in the order the income statement takes it, ending at net profit.

What good looks like. No single step swallowing a surprising share, and a bottom line that survives all of them.

If it rises or falls. The largest step is where the business really spends its money, and it is the one to watch year to year: a step that grows faster than revenue is what margin compression looks like before it reaches the margin chart.

Cash conversion

How much of each sale does ABBV turn into free cash flow?

→29 cents of every sales dollar became free cash in 2025, down 13 points since 2022.

What this measures

Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.

What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.

If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.

Spending intensity

How much of its revenue does ABBV spend on capex, R&D and stock pay?

→The biggest claim on each sales dollar is capital spending, at 2% of revenue (stock compensation 2%). That share has risen since 2022, so the cost of competing is climbing.

What this measures

Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.

What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.

If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.

Operating leverage

Does ABBV's operating profit grow faster than its revenue?

→Operating profit outgrew revenue in only 2 of the last 5 years. Costs are growing roughly in step with the business, so scale isn't yet paying for itself.

What this measures

How often operating profit grew faster than revenue, year by year. Fixed costs mean profit should rise faster than sales once those costs are covered.

What good looks like. Profit outgrowing revenue in most years, and by a widening margin in the good ones.

If it rises or falls. Leverage cuts both ways: the same fixed costs that multiply profit on the way up multiply the damage when sales fall. A business with strong operating leverage is a better business and a more volatile one.

Goodwill by acquisitionInsight

How much goodwill does AbbVie carry from each acquisition?

This insight is free with an account.

Sign up free to see it

→Allergan alone left $16.4B of goodwill on AbbVie's balance sheet, more than every other deal together ($3.4B). Goodwill is the part of a price that bought no asset anyone can name, and it sits there until the day it is written off.

Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30

Return on capital employed

Is ABBV's return on capital above what its capital costs?

→ABBV earns 16.6% on the capital it employs, comfortably above the 10% most investors treat as the cost of capital. It was 16.6% in 2022, so the trend is flat, and the pace is picking up.

What this measures

The same return as the card above, but every filed year, against a 10% line that stands in for what capital costs.

What good looks like. Years above the line, and a trend that is flat or rising rather than drifting down towards it.

If it rises or falls. A business earning above its cost of capital creates value by growing; one earning below it destroys value by growing. The 10% line is a convention, not a law, so read the distance from it rather than the crossing.

What does “Quality” actually mean?

Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.

How we scored it · 5 of 6 checks passed
✓Better gross margins than its sector71.5% vs 58.1% (sector 70th pct, n=113)
✓Runs leaner than its sector (operating margin)26.2% vs 10.5% (sector 70th pct, n=252)
✓Actually profitableTTM net income $6.3B
✕Earns well on shareholders' moneynegative equity
✓Earns a real return on the capital it employs18.0% vs 10.0%
✓Profits are cash, not accounting3.09 vs 0.80
IV

Financial health

●●●●●●3/6

Financially sound overall, with one or two things worth watching.

-debt unreported
0.8xnear-term bills coverage
6xearnings ÷ interest bill
$6.6Bcash plus short-term investments
Debt & cash

How much debt does ABBV carry, and do its profits cover the interest?

→Debt of $62.5B sits against $6.6B of cash. Earnings cover interest 5.8 times - adequate, with less room than it looks in a downturn.

What this measures

Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.

What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.

If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.

Near-term liquidity

Do ABBV's current assets cover the bills due within a year?

→Near-term liquidity is tight: 0.8x of current assets against a dollar due within the year, so ABBV is relying on trading through rather than on what it already holds. That is thinner than in 2012.

What this measures

Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.

What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.

If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.

Interest cover

How many times over can ABBV's operating profit pay its interest bill?

→Operating profit covers the interest bill 5.8x over. Cover was 55.9x in 2012, so the margin of safety has narrowed.

What this measures

Operating profit divided by interest expense - how many times over the year's earnings could pay the year's interest.

What good looks like. High and steady. Five times is a common floor; comfortably above it means the debt is being carried, not merely serviced.

If it rises or falls. It falls when profit falls or when borrowing costs rise, and a company can look safe on the level while the direction is telling you otherwise.

Cash conversion

How much of ABBV's revenue arrives as operating cash?

→30.3% of every dollar ABBV sold arrived as operating cash. Down from 35.8% in 2011.

What this measures

Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.

What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.

If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.

Shareholders' equity

Is ABBV's shareholder equity (book value) growing?

Equity is below zero after years of buybacks exceeding earnings, so debt-to-equity and return on equity are not published for ABBV: a ratio to a negative base means nothing.

→Shareholders' equity is negative at -$5.9B: liabilities exceed assets. Usually the mark of heavy buybacks or accumulated losses, and always worth understanding which.

What this measures

What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.

What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.

If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.

What does “Health” actually mean?

Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.

How we scored it · 3 of 6 checks passed
✕Comfortable near-term liquidity0.81 vs 1.50
✕Debt isn't dominatingnegative equity
–Debt trending the right wayunder 5 years of balance-sheet history
✓Earnings cover the interest5.79 vs 5.00
✓Converts sales to cash better than its sector30.3% vs 14.4% (sector 70th pct, n=274)
✓Self-fundingTTM free cash flow $18.2B
V

Shareholder returns

●●●●●●6/6

Shareholders are paid reliably and affordably, and the share count is not eroding their stake.

+0.30%bought back, TTM, over market value
+2.43%at the current rate
$13.6Bdividends plus buybacks
$976Mlast 12m, dilutes the buybacks
+12.5%since 2011 (split-adjusted)
Capital returned vs stock comp

Do ABBV's buybacks and dividends outweigh the stock it issues to staff?

→Shareholders received $980M in buybacks and $11.8B in dividends in 2025. The trailing twelve months come to $13.6B. Stock compensation issued $955M of new shares in the same year, offsetting 7% of that.

What this measures

Cash returned through buybacks and dividends, alongside the value of new shares issued to employees as compensation.

What good looks like. Returns comfortably larger than stock compensation, so the share count actually falls.

If it rises or falls. A company can announce billions in buybacks while issuing nearly as much stock to staff, and the two largely cancel. What reaches you is the net effect, which is why both bars are here rather than only the buyback.

Shareholder yield

What is ABBV's shareholder yield from dividends and buybacks?

→ABBV handed back 2.7% of its market value over the last twelve months, above the 2% this check asks for. Most of it is the dividend (2.4% against 0.3% of buybacks). Its own average is 6.8%, so less is coming back than usual.

What this measures

Dividends and buybacks, each as a percentage of what the company was worth that year. The dollar chart says how much came back; this says how much came back for the price.

What good looks like. A total that clears a couple of percent and holds. Which half it comes from matters less than whether it is sustained.

If it rises or falls. A yield rises when the price falls as readily as when the payout grows, so read a jump beside the price chart before treating it as generosity.

Share count change (split-adjusted)

Is ABBV's share count rising or falling?

→The share count shrank 0.0% in 2025, averaging 0.1% a year over three years. Buybacks are concentrating your ownership: the same business, split fewer ways.

What this measures

The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.

What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.

If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.

Dividend per share (split-adjusted)

Is ABBV's dividend per share growing?

→The dividend per share reached $6.67 in 2025, compounding +6% a year since 2020.

What this measures

The dividend paid on one share each year, adjusted for splits so a share today compares with a share ten years ago.

What good looks like. A payment that rises steadily. A long unbroken run of rises is a management commitment as much as a number.

If it rises or falls. A cut is one of the strongest signals a board can send, because they know how it will be read. Check it against the payout chart: a rising dividend the business cannot cover is a promise borrowed against.

Dividend yield

What is ABBV's dividend yield at today's price?

→ABBV's dividend at its current rate is 2.43% of today's price.

What this measures

The dividend paid over the trailing twelve months as a percentage of the share price, at each quarter's (or year's) average price and at today's.

What good looks like. A yield in line with the company's own history. A yield far above it is usually the price falling, not the dividend rising.

If it rises or falls. Yield moves for two opposite reasons, and they are easy to confuse: a bigger dividend, or a cheaper share. The dividend-per-share chart above tells you which one happened.

Payout quality

What share of its profit and cash does ABBV pay out as dividends?

→The dividend consumed 280% of profit and 66% of free cash flow in 2025. Over the trailing twelve months it is 192%. That is a thin cushion: a bad year would put the payment under real pressure.

What this measures

The dividend as a share of profit, and as a share of free cash flow. Two views of the same question, because profit and cash are not the same thing.

What good looks like. Comfortably under 75% of profit and under 90% of free cash flow, which leaves room to keep paying through a weak year.

If it rises or falls. A payout ratio climbing towards 100% means the dividend is consuming everything the business earns, so the next bad year has to be funded by borrowing or by a cut. Above 100% it is already being funded from somewhere else.

Dilution against what it bought

Has ABBV's revenue per share grown faster than its share count?

Change since 2011. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.

→ABBV issued 12% more shares from 2011 to 2025, but revenue per share still rose 212%. The dilution bought more growth than it cost existing holders.

What this measures

The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.

What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.

If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.

Why compare buybacks with stock compensation?

A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.

How we scored it · 6 of 6 checks passed
✓Share count isn't climbingshares down 0.3% over 3 years
✓Buybacks outpace the stock issued to staff$1.5B bought back vs $976M of stock compensation
✓What it hands back fits inside its cash flow74.9% vs 100.0%
✓Meaningful yield to owners (dividends and buybacks)$13.6B returned, 2.7% of market value
✓Reliable payer, never cutpaid 10/10 years, worst year-on-year change 4.6%
✓Dividend per share growing ahead of inflation16.4% vs 9.0%
VI

Trend

●●●●●●6/6

A confirmed uptrend: above the cloud, above both trend lines, and the readings agree.

+22.9%the long-term trend line
+10.6%S&P 500 (SPY): +3.6%
+26.9%S&P 500 (SPY): +15.0%
-1.3%drawdown from peak
Trend

Which way is ABBV's share price trending?

Price chart loads as you scroll…

Chart by TradingView

→ABBV is in a clear uptrend: the price is above the cloud where recent trading settled, and that cloud is still rising underneath it. The last two weeks and the month-ago comparison both point up, so the shorter readings back the trend.

How the trend above is worked out

The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.

How we scored it · 6 of 6 checks passed
✓Price above the Kumo cloud$285.19 against a cloud top of $254.46
✓Price above the Tenkan and the Kijun$285.19 against the Tenkan (9 sessions) at $281.71 and the Kijun (26) at $273.85
✓Tenkan above the KijunTenkan $281.71 above the Kijun $273.85, 23 sessions since they crossed
✓The Senkou cloud ahead is risingthe Senkou spans already drawn for the next 26 sessions are rising
✓Chikou above the price 26 sessions back$285.19 against $260.91 26 sessions ago
✓Beating the S&P 500 over 12 months26.9% vs 15.0%
VII

Insider activity

informational
$0.00their own money
$19Moften pre-scheduled
6of the last filings
54grants · exercises · tax
Open-market flow

Are ABBV's insiders buying or selling shares with their own money?

→Since December 2023, insiders sold $232M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 224 transactions were grants, option exercises or tax withholding, which say nothing either way.

What this measures

Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.

What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.

If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.

The record

Who did what, exactly?

DateInsiderRoleTypeSharesPriceValue
2026-08-14Nicholas DonoghoeEVP, CHIEF BUS/STRAT OFFICERexercise32,710$79.02$2.58M
2026-08-14Nicholas DonoghoeEVP, CHIEF BUS/STRAT OFFICERSELL32,710$250.00$8.18M
2026-03-04David Ryan PurdueSVP, ControllerSELL5,230$233.56$1.22M
2026-03-02Perry C SiatisEVP, GC AND SECRETARYSELL5,777$233.51$1.35M
2026-03-02Perry C SiatisEVP, GC AND SECRETARYSELL10,291$234.66$2.41M
2026-03-02Perry C SiatisEVP, GC AND SECRETARYSELL2,600$235.26$611,676
2026-02-27Demetris D CrumEVP, CHIEF HR OFFICERtax1,594$232.08$369,936
2026-02-27Roopal ThakkarEVP, R&D and CSOtax8,037$232.08$1.87M
2026-02-27Robert A. MichaelCHAIRMAN OF THE BOARD AND CEOtax36,523$232.08$8.48M
2026-02-27Jeffrey Ryan StewartEVP, CHIEF COMMERCIAL OFFICERtax23,812$232.08$5.53M
Why do the transaction types matter so much?

Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.

VIII

Ownership

informational
75.6%on Form 13F, 30 June 2026
0.1%officers, directors, founders
34.3%together
8last 12 months
Top holders

Who owns AbbVie stock?

Fund managers filing Form 13F held 75.6% of the company's shares on 30 June 2026. The largest holder is BlackRock, Inc., with 8.5%. Insiders hold 0.1%.

#HolderStakeSharesValueChange
1BlackRock, Inc.Fund manager8.46%149.5M$42.6B-0.8%
2Vanguard Capital Management LLCFund manager6.53%115.4M$32.9B+0.4%
3State Street CorpFund manager4.67%82.6M$23.6B+1.7%

The full list of top holders is free with an account

Sign up free

Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.

Congress

Are members of Congress trading AbbVie stock?

5 members of the House reported 8 trades in AbbVie in the last 12 months: one buy and 7 sales.

MemberTradeAmountTraded
Pete SessionsR-TXSold$15K to $50K14 September 2026
Josh GottheimerD-NJ · jointSold$1K to $15K5 May 2026
Julie JohnsonD-TX · jointSold$1K to $15K18 December 2025
Julia LetlowR-LASold$1K to $15K8 December 2025
Julie JohnsonD-TX · jointSold part$1K to $15K13 November 2025

Every congressional trade is free with an account

Sign up free

Source: Periodic Transaction Reports filed with the Clerk of the House under the STOCK Act, within 45 days of a trade. Amounts are the ranges the law asks for. The Senate's reports are not included yet. All Congress trades

Where does this list come from?

Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.

§

Recent filings

A short weekly note on what changed in the numbers, coming soon.One email a week: the charts that mattered, nothing else.
Where these numbers come from. Financial statements: US SEC EDGAR (XBRL company facts, as filed - including restatements; hatched chart bars are fourth quarters derived from annual filings), current to 2026-06-30. Prices: delayed end-of-day, as of 2026-10-22. Scores are counts of the transparent pass/fail checks shown in each chapter; every sentence on this page is computed from the data shown, except the labelled editorial note. Missing data is shown as missing, never estimated. Nothing here is investment advice. Terms · Methodology